Fennec Pharmaceuticals Management
Management criteria checks 2/4
Fennec Pharmaceuticals' CEO is Rosty Raykov, appointed in Jul 2009, has a tenure of 14.83 years. total yearly compensation is $2.54M, comprised of 23.9% salary and 76.1% bonuses, including company stock and options. directly owns 0.69% of the company’s shares, worth $1.72M. The average tenure of the management team and the board of directors is 8.5 years and 10.1 years respectively.
Key information
Rosty Raykov
Chief executive officer
US$2.5m
Total compensation
| CEO salary percentage | 23.9% |
| CEO tenure | 14.8yrs |
| CEO ownership | 0.7% |
| Management average tenure | 8.5yrs |
| Board average tenure | 10.1yrs |
Recent management updates
Recent updates
Risks To Shareholder Returns Are Elevated At These Prices For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
Apr 18
Earnings Update: Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Just Reported And Analysts Are Boosting Their Estimates
Nov 09Fennec wins FDA approval of Pedmark for chemotherapy-induced ototoxicity in children
Sep 20Buying Fennec Pharma Ahead Of September PDUFA For Pedmark
Aug 23Fennec Pharmaceuticals secures up to $45M financing facility from Petrichor
Aug 01Fennec Pharmaceuticals: Will Pedmark Make It To Market At Second Time Of Asking?
Oct 29Fennec Could See Upside If Pedmark Gets Approved
Jul 29Fennec Pharmaceuticals (FENC) Investor Presentation - Slideshow
Jun 18Fennec Pharma resubmits PEDMARK application in U.S.
May 28Fennec Pharmaceuticals (NASDAQ:FENC) Is In A Good Position To Deliver On Growth Plans
May 26Breakeven On The Horizon For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
Apr 01Do Institutions Own Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Shares?
Mar 02Have Insiders Been Selling Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Shares This Year?
Jan 26Companies Like Fennec Pharmaceuticals (NASDAQ:FENC) Are In A Position To Invest In Growth
Dec 22Fennec Pharmaceuticals EPS misses by $0.05
Nov 16Fennec Pharmaceuticals: The Compensation Is What's Missing
Nov 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$3m | US$607k | -US$16m |
| Sep 30 2023 | n/a | n/a | -US$20m |
| Jun 30 2023 | n/a | n/a | -US$26m |
| Mar 31 2023 | n/a | n/a | -US$26m |
| Dec 31 2022 | US$614k | US$503k | -US$24m |
| Sep 30 2022 | n/a | n/a | -US$21m |
| Jun 30 2022 | n/a | n/a | -US$17m |
| Mar 31 2022 | n/a | n/a | -US$16m |
| Dec 31 2021 | US$3m | US$468k | -US$17m |
| Sep 30 2021 | n/a | n/a | -US$16m |
| Jun 30 2021 | n/a | n/a | -US$18m |
| Mar 31 2021 | n/a | n/a | -US$19m |
| Dec 31 2020 | US$2m | US$430k | -US$18m |
| Sep 30 2020 | n/a | n/a | -US$18m |
| Jun 30 2020 | n/a | n/a | -US$14m |
| Mar 31 2020 | n/a | n/a | -US$14m |
| Dec 31 2019 | US$1m | US$489k | -US$13m |
| Sep 30 2019 | n/a | n/a | -US$12m |
| Jun 30 2019 | n/a | n/a | -US$13m |
| Mar 31 2019 | n/a | n/a | -US$11m |
| Dec 31 2018 | US$1m | US$350k | -US$10m |
| Sep 30 2018 | n/a | n/a | -US$9m |
| Jun 30 2018 | n/a | n/a | -US$9m |
| Mar 31 2018 | n/a | n/a | -US$8m |
| Dec 31 2017 | US$450k | US$263k | -US$7m |
Compensation vs Market: Rosty's total compensation ($USD2.54M) is above average for companies of similar size in the US market ($USD1.64M).
Compensation vs Earnings: Rosty's compensation has increased whilst the company is unprofitable.
CEO
Rosty Raykov (47 yo)
14.8yrs
Tenure
US$2,540,940
Compensation
Mr. Rostislav Raykov, also known as Rosty, has been the Chief Executive Officer of Fennec Pharmaceuticals Inc. since July 2009. Mr. Raykov is an Independent Director of Lavras Gold Corp. since April 1, 202...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 14.8yrs | US$2.54m | 0.69% $ 1.7m | |
| Chief Financial Officer | 8.5yrs | US$1.31m | 0.38% $ 957.2k | |
| Chief Operating Officer | less than a year | US$1.50m | 0% $ 0 | |
| Controller | 8.5yrs | no data | no data | |
| President of Pharstat Inc | no data | no data | no data |
8.5yrs
Average Tenure
48yo
Average Age
Experienced Management: FENC's management team is seasoned and experienced (8.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 14.8yrs | US$2.54m | 0.69% $ 1.7m | |
| Independent Director | 12.8yrs | US$173.18k | 0.17% $ 420.8k | |
| Independent Chairman of the Board | 10.1yrs | US$225.23k | 0.79% $ 2.0m | |
| Independent Director | 4.7yrs | US$153.81k | 0% $ 0 | |
| Independent Director | 7.8yrs | US$166.31k | 0% $ 0 |
10.1yrs
Average Tenure
68yo
Average Age
Experienced Board: FENC's board of directors are seasoned and experienced ( 10.1 years average tenure).